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Abstract
Cellular levels of phosphatidylinositol 4-phosphate (PI4P) have been shown to be upregulated during RNA replication of
several viruses, including the HCV replicon model. However, whether PI4P is required in an infectious HCV model remains
unknown. Moreover, it is not established whether the host transport machinery is sequestered by the generation of PI4P
during HCV infection. Here we found that PI4P was enriched in HCV replication complexes when Huh7.5.1 cells were
infected with JFH1. HCV replication was inhibited upon overexpression of the PI4P phosphatase Sac1. The PI4P kinase
PI4KIIIb was also found to be required for HCV replication. Moreover, the vesicular transport proteins ARF1 and GBF1
colocalized with PI4KIIIb and were both required for HCV replication. During authentic HCV infection, PI4P plays an integral
role in virus replication.
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Introduction
Hepatitis C virus (HCV), a positive-strand RNA virus of the
family Flaviviridae, is one of the most prominent health threats in
the world today, infecting more than 170 million persons globally
[1]. Current HCV treatment with pegylated interferon a and
ribavirin. produces sustained virologic response (SVR) in 42–52%,
65–85% and 76–82% of individuals infected with HCV genotype
1, HCV genotypes 4, 5 or 6 and HCV genotypes 2 or 3,
respectively [2,3]. Many inhibitors targeting HCV viral proteins
have been discovered with many of them at late stages of clinical
trials. Currently several new classes of antiviral drugs targeting
NS5A and NS5B are at various stages of preclinical and clinical
studies [4]. In 2011 two NS3 protease inhibitors, telaprevir and
boceprevir, have been approved. An enhanced sustained virologic
response (SVR) can be achieved through addition of protease
inhibitors. Recent trials in patients with HCV genotype 1 infection
combining the standard of care (SOC) with telaprevir or
boceprevir have found that SVR rates is 61–75% for telaprevir
[5,6,7,8] or 67–75% for boceprevir [9,10,11]. While new agents
directly targeting HCV proteins have been developed, they are
limited by the selection of resistant variants. Understanding the
cell biology of viral replication is critical for the development of
novel host-directed antiviral strategies against HCV that could
circumvent the selection of resistant viral variants.
The 9.6 kb genome of HCV encodes structural proteins
including core, E1 and E2 and the nonstructural proteins
consisting p7, NS2–NS5 which support viral RNA replication.
HCV displays a remarkable capacity to survive and replicate in its
host [12]. To be successful in establishing persistent infection,
HCV hijacks host cellular processes at several levels. Among these
disrupted processes are lipid signaling and metabolism
[13,14,15,16], which provide a novel insight into host-pathogen
interactions.
As a key member of the phosphatidylinositol (PI), phosphatidy-
linositol 4-phosphate (PI4P) is the principle phosphoinositide in the
Golgi apparatus and acts as a targeting signal for Golgi associated
proteins [17]. PtdIns 4-kinases (PI4K) phosphorylate PI at the 49
position to yield PI4P. Eukaryotes contain two classes of PtdIns 4-
kinase, termed type II and type III. Type II PtdIns 4-kinases make
up a significant fraction of the PtdIns 4-kinase activities in plasma
membrane, whereas type III PtdIns 4-kinases, namely PI4KIIIa
and PI4KIIIb, serve to generate pools of PI4P in Golgi [18]. Sac1,
a type II membrane protein that localizes to the ER and Golgi
apparatus, is a principle pathway for PI(4)P dephosphorylation in
vivo [19]. Investigating the mechanisms by which pathogens
exploit PI4P could not only identify potential new antiviral targets
but will also reveal additional insights into the cellular function of
PI4P.
Recently, Hsu et al [20] found that PI4P is involved in HCV
replication in a replicon model and that the distribution of PI4P
changes in cells that harbor stable viral polyproteins with a
selectable marker. Studies from several groups demonstrated that
NS5A recruited PI4KIIIa to the viral replication compartment
and stimulated PI4KIIIa activity for HCV replication [21,22,23].
In this study, we assessed whether PI4P is similarly involved in
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32135HCV replication in the fully infectious JFH1 model. Moreover, we
found that two vesicular transport proteins, ARF1 and GBF1,
colocalized with PI4KIIIb, and that both proteins were required
for HCV replication.
Results
PI4P is rearranged during HCV infection
To assess the localization of PI4P during HCV infection, Huh
7.5.1 cells were infected with the cell culture infectious JFH1 for 3
days followed by immunofluorescence microscopy. As shown in
Figure 1A, PI4P staining in JFH1 infected-Huh7.5.1 (JFH1) cells
was significantly stronger than that in the mock infected cells
(Figure 1A). The b–COP is a Golgi marker. To validate that
upregulation of PI4P relied on HCV replication, we infected
Huh7.5.1 cells with JFH1 in the presence of 90 IU/ml IFN to
repress HCV replication and found that the PI4P signal is reduced
by IFN (Figure 1B), Moreover, PI4P partially colocalized with
NS5A in the JFH1 model (Figure 1C). Taken together, PI4P is
rearranged during HCV infection and could define the viral
replication compartment.
Sac1 overexpression inhibits HCV replication
Sac1 is a phosphoinositide lipid phosphatase that removes the
phosphate residue from the inositol head group of PI(4)P [24]. To
explore the importance of PI4P in HCV replication, we
overexpressed Sac1 and then infected Huh7.5.1 cells with JFH1.
The expression of Sac1GFP was confirmed by western blot
(Figure 2A) and cellular PI4P was depleted by Sac1GFP
(Figure 2B). As shown in Figure 2C and 2D, HCV replication as
measured by HCV core and NS5A staining was strongly inhibited
by overexpression of Sac1. To further establish the effect of Sac1
overexpression on HCV replication, we infected Huh7.5.1 cells
with JFH1 and total RNA was isolated for reverse transcription
and subsequent quantitive PCR ana lysis. We observed modest
reduction of actin-normalized JFH1 RNA levelswith overexpres-
sion of Sac1GFP of about 20% (Figure 2E), but this appears to
have been correlated with reduced efficiency of Sac1 transfection
in Huh7.5.1 cells. Next Huh7.5.1 cells were transfected with
pEGFP-Sac1 and infected with Jc1FLAG2(p7-nsGluc2A) for 3
days. Gaussia luciferase activity and cellular ATP levels were
measured. The normalized luciferase activities were then divided
by the normalized luciferase activity from mock treatment. The
reduction of Jc1 measured by lucifease activity by overexpression
of Sac1GFP is only about 35% (Figure 2F). These data
demonstrated the role of Sac1 for HCV replication and confirm
an essential role for PI4P in HCV replication.
PI4KIIIb is required for HCV replication
To gain insight into the importance of PI4P levels regulated by
PI4P kinases, we knocked down the PI4P kinase PI4KIIIb in
Huh7.5.1 cells and infected these cells with JFH1. As Figure 3A
shows, RNA replication of JFH1 is reduced upon knock down of
PI4KIIIb by siRNA. To further confirm the role of PI4KIIIb,w e
knocked down PI4KIIIb in uninfected Huh7.5.1 cells and cells
infected with the infectious virus Jc1FLAG2(p7-nsGluc2A). We
found that the replication of Jc1FLAG2(p7-nsGluc2A) as mea-
sured by luciferase activity is markedly reduced with PI4KIIIb
knockdown (Figure 3B). PIK93 is an inhibitor of PI4KIIIb [25].
We treated Huh7.5.1 cells with increasing doses of PIK93 and
infected with either JFH1 or Jc1FLAG2(p7-nsGluc2A) . PIK93 did
not reduce cell viability as measured by cellular ATP levels even at
doses of 6.4 mM (Figure 3D). At a dosage of 0.8 mM, PIK93
inhibited HCV replication by around 45% as assessed by QPCR
(Figure 3C) or luciferase activity (Figure 3D). Taken together,
PI4KIIIb is required for HCV replication.
PI4KIIIb colocalizes with ARF1 or GBF1
Activated ARF1 is responsible for the delivery of PI4KIIIb to
the Golgi membrane where the local concentration of PI4P is
enriched [26]. We examined whether ARF1 colocalized with
PI4KIIIb during HCV infection. We transfected an HA tagged
ARF1 plasmid to Huh7.5.1 cells and infected them with JFH1 or
mock. We found that ARF1 colocalized with PI4KIIIb (Figure 4A).
We also found that one of the GEFs (guanine nucleotide exchange
factors) for ARF1, GBF1, colocalized with PI4KIIIb (Figure 4B).
These data suggest that GBF1 and ARF1 generate sufficient local
concentrations of PI4P to enable HCV infection.
ARF1 is required for HCV replication
Next we investigated the effect of ARF1 inhibition on HCV
replication. When Huh7.5.1 cells were knocked down ARF1 by
siRNA (Figure 5A and 5B) and infected with JFH1, HCV
replication was reduced 10-fold as assessed by western blot
(Figure 5A) and QPCR (Figure 5B). Next Huh7.5.1 cells were
Figure 1. PI4P is rearranged during HCV infection. (A) Huh 7.5.1
cells infected or uninfected with JFH1 were stained with antibodies
against PI4P (red) or b-COP (green). (B) Huh 7.5.1 cells infected with
JFH1 were treated with 90 IU/ml IFN or mock infection and then stained
with antibodies against PI4P (red) or b-COP (green). (C) Huh 7.5.1 cells
infected or uninfected with JFH1 were stained with antibodies against
PI4P (red) or NS-5A (green).
doi:10.1371/journal.pone.0032135.g001
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and infected with Jc1FLAG2(p7-nsGluc2A) for 3 days. Gaussia
luciferase activity and cellular ATP levels were measured. The
normalized luciferase activities were then divided by the
normalized luciferase activity from mock treatment. Both siRNAs
could strongly reduce HCV replication (Figure 5C).These data
indicate that ARF1 is required for HCV replication.
GBF1 is required for HCV replication
To examine whether GBF1 is critical for HCV replication,
Huh7.5.1 cells were treated with the GBF1 inhibitor GCA or
ARF1 inhibitor BFA, infected with JFH1, and assessed for HCV
replication. Both BFA and GCA reduced HCV RNA replication
up to 10-fold as shown in Figure 6A. Morevoer HCV core protein
level was reduced by GCA (Figure 6B). Two siRNAs against GBF1
also inhibited HCV replication (Figure 6C and 6D). These data
confirm that GBF1 is required for HCV replication.
Discussion
Inositol phospholipids play important regulatory roles in a
variety of cellular processes. In total, seven species of phospho-
inositides are generated by the reversible phosphorylation of the
Figure 2. Sac1 overexpression inhibits HCV replication. (A) Huh 7.5.1 cells transfected with pEGFP-Sac1 or mock and then cell lysates were
analyzed by immunoblotting with the indicated antibodies. (B) Huh 7.5.1 cells transfected with pEGFP-Sac1 and infected with JFH1 were stained with
antibodies against PI4P (red). (C) Huh 7.5.1 cells transfected with pEGFP-Sac1 and infected with JFH1 were stained with antibodies against HCV core
(red). (D) Huh 7.5.1 cells transfected with pEGFP-Sac1 and infected with JFH1 were stained with antibodies against HCV NS5A (red). (E) Huh 7.5.1 cells
were transfected with pEGFP-Sac1 and infected with JFH1. Total RNA was isolated and reversely transcribed and then quantitive PCR was performed.
(F) Huh7.5.1 cells were transfected with pEGFP-Sac1 and infected with Jc1FLAG2(p7-nsGluc2A) for 3 days. Gaussia luciferase activity and cellular ATP
levels were measured. The normalized luciferase activities were then divided by the normalized luciferase activity from mock treatment.
doi:10.1371/journal.pone.0032135.g002
ARF1 and GBF1 Generate PI4P Environment
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e32135Figure 3. PI4KIIIb is required for HCV replication. (A) Huh7.5.1 cells were treated with siRNA against PI4KIIIb or control siRNA for 3 days and
then infected with JFH1 for 3 days. Total RNA was isolated and reversely transcribed and then quantitive PCR was performed. (B) Huh7.5.1 cells were
treated with siRNA against PI4KIIIb or control siRNA for 3 days and then infected with Jc1 for 3 days. Gaussia luciferase activity and cellular ATP levels
were measured. The normalized luciferase activities were then divided by the normalized luciferase activity from mock treatment. (C) Huh7.5.1 cells
were treated with different dosages of PIK93 as indicated for 1 hour and then infected with JFH1 for 3 days. Total RNA was isolated and reversely
transcribed and then quantitive PCR was performed. (D) Huh7.5.1 cells were treated with different dosages of PIK93 as indicated for 1 hour and then
infected with Jc1FLAG2(p7-nsGluc2A) for 3 days. Gaussia luciferase activity and cellular ATP levels were measured. The normalized luciferase activities
were then divided by the normalized luciferase activity from mock treatment.
doi:10.1371/journal.pone.0032135.g003
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interactions on membrane-cytosol interfaces [27]. Each of the
seven phosphoinositides has a unique spatial distribution with a
predominant localization in subcellular organelles that define their
identities. For example, PI(4,5)P2 is mainly found in the plasma
membrane, PI3P in endosomes and phagosomes, PI(3,5)P2 in
vacuoles and late endosomes, while PI4P is enriched in the Golgi
complex region [17,27]. The differential intracellular distribution
of phosphoinositides, together with their high turnover rate makes
these lipids optimal regulators for precise intracellular activities,
such as signaling transduction, cytoskeleton organization and
membrane dynamics.
Investigation of PI metabolism perturbed by HCV may provide
significant opportunity to understand the regulation of PI during
viral infection, identifying specific PI effectors for further dissection
of their functions and assessment as plausible therapeutic
candidates. Here we found that PI4P is enriched in HCV
replication complexes. In the report of Hsu [20], NS5A clearly
colocalizedwith PI4P in the HCV replicon cell. In contrast, in our
study, PI4P only partially colocalized with NS5A in the JFH1
model (Figure 1B), suggesting that the upregulation and
rearrangement of PI4P during authentic HCV infection differs
from that of the replicon model, which invariably overexpresses
viral proteins.
To understand the spatial and temporal restriction of PI4P
during virus infection, it becomes necessary to identify the
phosphoinositide kinases and phosphatases involved in PI4P
homeostasis and their regulation. Sac1 is an ER- and Golgi-
complex-associated phosphoinositide phosphatase that dephos-
phorylates PI4P during retrograde transport from Golgi to ER,
thus ensuring the enrichment of PI4P in the Golgi complex
[19,24]. When we expressed Sac1 to deplete PI4P, HCV
replication was repressed, which suggests that PI4P is crucial for
HCV replication.
The importance of PI4P in Golgi structure and function was
revealed by mutations of the PI4P kinase Pik1, which resulted in
an accumulation of abnormal membrane intermediates with defect
of transport to plasma membrane [17]. The mammalian Pik1
homolugue is PI4KIIIb. However, PI4KIIIa has been identified
by several RNAi screens as a host factor for HCV replication
[21,28,29,30,31,32]. NS5A is able to recruit PI4KIIIa to the viral
replication compartment and stimulate PI4KIIIa activity, which is
crucial for HCV replication [21,22,23]. Thus it is well established
that PI4P generated by PI4KIIIa is important for HCV
Figure 4. PI4KIIIb colocalizes with ARF1 or GBF1. (A) Huh 7.5.1
cells transfected with a HA-tagged ARF1 construct and infected with
JFH1 or mock were stained with antibodies against HA (red) or PI4KIIIb
(green). (B) Huh 7.5.1 cells infected with JFH1 or mock were stained with
antibodies against PI4KIIIb (red) or GBF1 (green).
doi:10.1371/journal.pone.0032135.g004
Figure 5. ARF1 is required for HCV replication. (A) Huh7.5.1 cells were treated with siRNA against PI4KIIIb or control siRNA for 3 days and then
infected with JFH1 for 3 days. Cell lysates were analyzed by immunoblotting with the indicated antibodies. (B) Huh7.5.1 cells were treated with siRNA
against ARF1 or control siRNA for 3 days and then infected with JFH1 for 3 days. Total RNA was isolated and reverse transcribed and then quantitive
PCR was performed. (C) Huh7.5.1 cells were treated with siRNA against ARF1(#6 sequence or #8 sequence) or control siRNA and then infected with
Jc1FLAG2(p7-nsGluc2A) for 3 days. Gaussia luciferase activity and cellular ATP levels were measured. The normalized luciferase activities were then
divided by the normalized luciferase activity from mock treatment.
doi:10.1371/journal.pone.0032135.g005
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e32135Figure 6. GBF1 is required for HCV replication. (A) Huh7.5.1 cells were treated with different dosages of BFA or GCA as indicated for 1 hour and
then infected with JFH1 for 2 days. Total RNA was isolated and reverse transcribed and then quantitive PCR was performed. (B) Huh7.5.1 cells were
treated with 20 mM GCA for 1 hour and then infected with JFH1 for 3 days. Cell lysates were analyzed by immunoblotting with the indicated
antibodies. (C) Huh7.5.1 cells were treated with siRNA against GBF1 or control siRNA for 3 days and then infected with JFH1 for 3 days. Cell lysates
were analyzed by immunoblotting with the indicated antibodies. (D) Huh7.5.1 cells were treated with siRNA against GBF1 or control siRNA for 3 days
and then infected with JFH1 for 3 days. Total RNA was isolated and reverse transcribed and then quantitive PCR was performed.
doi:10.1371/journal.pone.0032135.g006
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responsible for generating PI4P during HCV replication [20,33].
Here, we confirm that PI4KIIIb is critical for HCV replication in
JFH1 and Jc1 infection models. Nonetheless, it remains possible
that both PI4KIIIa and PI4KIIIb are required for HCV
replication.
Beside phosphoinositides, another class of molecules mediated
the recruitment of cytosolic protein to specific membrane
compartment is small GTPases [34]. They shuttle between GTP
(active) and GDP (inactive) bound states with the help of
Guanidine nucleotide exchange factors (GEFs) and GTPase
activating proteins (GAP), which stimulate the GTP loading and
hydrolysis respectively. ARF1 regulates the vesicular transport
from Golgi to ER [34]. It has been shown that ARF1 promotes the
production of PI4P within the Golgi membrane by recruiting
PI4KIIIb [26]. Mounting functional and mechanistic evidence
suggests that components of the COPI pathway act as host lipid
effectors for a number of pathogens, such as poliovirus [35,36,37],
HIV [35] and vaccinia virus [38]. Investigating the mechanisms by
which viruses exploit COPI, as well as the mechanisms by which
they inhibit COPI, will not only identify possible new antiviral
targets but will also reveal additional insight into COPI normal
cellular function. In this study we found that during HCV
infection, ARF1 and its exchange factor GBF1 colocalized with
PI4KIIIb on the HCV replication complex. Recently, we
conducted an RNAi screen and identified the core factor of COPI
pathway coatomer as a host factors involved in HCV replication
[30]. Other two groups found that key COPI pathway factors,
including GBF1 and ARF1 are critical for HCV replication
[39,40]. Here we also show that ARF1 and GBF1 are required for
HCV replication, further establishing that COPI pathway proteins
are pro-viral factors for HCV. Moreover, we propose that one of
the mechanisms of COPI participating in the HCV replication is
to divert PI4KIIIb from the Golgi complex to the viral replication
compartment to generate a new PI4P enriched environment.
Further work is necessary to identify viral proteins that are
involved in targeting PI4KIIIb, ARF1 and GBF1 to the replication
complex.
During the lifecycle of HCV, many host cellular processes are
subverted. For instance, lipid droplets are crucial for the formation
of infectious HCV virus particles [16]. A number of host and viral
proteins are recruited to the HCV replication complex. The
accuracy of protein targeting may depend on the restriction and
the generation of PI4P in this replication organelle. Several PI4P
binding proteins such as OSBP1 [41] and CERT [42] that
contains PI4P binding motif have been identified as host factors for
HCV replication. OSBP1 and CERT can recognize PI4P by lipid-
specific targeting domains to mediate organelle-specific recruit-
ment. Further investigations of more host and viral PI4P
associated proteins are required to elucidate the detailed
mechanism of the role of PI4P in HCV replication.
The HCV transmembrane protein NS4B is able to induce the
membranous web and could recruit the polymerase complex to
the HCV RNA. Great efforts have been made to identify
pharmacological inhibitors of NS4B [43]. However whether
PI4P is involved in membranous web formation or not is
unknown; further study is are needed.
In conclusion, during authentic HCV infection, PI4P plays an
integral role in virus replication. It is synthesized in the RNA
replication complex by PI4KIIIb, which is recruited specifically to
the replication complex by host transport proteins GBF1 and
ARF1. Our current findings suggest that the blockade of PI4P
formation is a potentially novel, host-directed antiviral target that
could complement more conventional antiviral therapy directed at
viral protein targets.
Materials and Methods
Cells, virus and reagents
Huh7.5.1 cells were grown in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% fetal bovine serum
(FBS). Infectious JFH1 plasmid was obtained from Dr. Takaji
Wakita and inoculated as previously described [44]. The infectious
plasmid Jc1FLAG2(p7-nsGluc2A) expressing Gaussia luciferase was
obtained from Dr. Charles Rice [45]. The PI4KIIIb inhibitor
PIK93 was obtained from Symansis (Auckland, New Zealand).
BFA and GCA were obtained from Sigma Life Science and
Biochemicals (St. Louis, MO.). Construct pEGFP-Sac1 was gift
from Dr. Peter Mayinger [46].
Western blotting
Cells were lysed using radioimmune precipitation assay (RIPA)
buffer containing 1% NP-40, 0.1% SDS, 10 mM Tris-HCl
(pH 7.4), 1 mM EDTA, 150 mM NaCl and protease inhibitor
cocktail and subsequently sonicated. Proteins were separated by
SDS-PAGE with NuPAGE Novex pre-cast 4–12% Bis-Tris
gradient gels (Invitrogen, Carlsbad, CA) and transferred to PVDF
membranes. The primary antibodies used including mouse anti-
GBF1 (BD Biosciences), mouse anti-ARF1 (Novus Biologicals,
Littleton, CO), mouse anti-HCV core (Affinity BioReagents Inc.,
Golden, CO), mouse anti-actin (Sigma Life Science and
Biochemicals, St. Louis, MO). Secondary antibodies were HRP-
conjugated ECL donkey anti-rabbit IgG and HRP-conjugated
ECL sheep anti-mouse IgG (Amersham Biosciences, Piscataway,
NJ). The ECL Western Blotting Detection Kit (Amersham
Biosciences, Piscataway, NJ) was used to detect Chemiluminescent
signals.
Immunofluorescence microscopy
Huh7.5.1 or JFH1 cells were fixed with 4% paraformaldehyde
at RT, permeabilized using 0.5% TritonX-100, and blocked with
3% BSA in PBS. The primary antibodies used in this paper were
mouse anti-HCV core (ViroGen Co., Watertown, MA), NS5A
(Virogen, Watertown, MA), mous anti-PI4P (Echelon Biosciences,
Salk Lake City, UT), rabbit anti-b-COP (Abcam, Cambridge,
MA), mouse anti-GBF1 (BD Biosciences), mouse anti-HA (Cell
Signaling Technology, Danvers, MA), rabbit anti-PI4KIIIb
(Millipore). The secondary antibody was goat anti-mouse-Alexa
Fluor 488 (Invitrogen, Carlsbad, CA). Immunofluorescence was
observed using Nikon Eclipse 800 microscopy with the Bio-Rad
Radiance 2000 confocal fluorescence microscope system (Bio-Rad
Laboratories, Hercules, CA).
Luciferase Assay
HCV replication in Jc1FLAG2(p7-nsGluc2A)-infected Huh
7.5.1 cells was determined by monitoring Gaussia luciferase activity
(Promega, Madison, WI).
siRNA and transfection
Indicated siRNAs were transfected into cells using Lipofecta-
mine
TM RNAiMAX Transfection Reagent (Invitrogen, Carlsbad,
CA). Negative control siRNA was from QIAGEN. All siRNAs
used for gene knock-down were from Dharmacon and were as
follows: PI4KIIIb, Dharmacon J-006777-09 (CCUUUAA-
GCUGACCACAGA)(#9), J-006777-12 (GGACUCACCAGCG-
CUCUAA) (#12); ARF1 Dharmacon D-011580-06 (CGGCCG-
AGAUCACAGACAA)(#6); D-011580-08 (GAACCAGAAGU-
ARF1 and GBF1 Generate PI4P Environment
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CACCUACUAUCUCU), J-019783-08 (CCACUGCUGUCACU
CUCUA). The protein expression of each gene knock down was
confirmed by Western blotting or QPCR.
Cell Viability Assay
Cell viability was monitored using the Cell Titer-Glo Lumines-
cent Cell Viability Assay Kit (Promega, Madison, WI) according to
the manufacturer’s protocol.
Quantitative PCR (qPCR)
Total cellular and viral RNA was isolated post infection using
RNeasy Mini columns (QIAGEN) and reverse transcribed by
random priming with the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems; Foster City, CA), then
quantified by real-time PCR using the DyNAmo HS SYBR Green
qPCR kit (Finnzyme; Espoo, Finland). The primers are listed in
Table 1.
Statistics
Data analysis was performed using a 2-tailed Student’s t-test.
Data are expressed as mean 6 SD of at least three sample
replicates, unless stated otherwise.
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